Table 2: Differences in quality of life (SF-36 questionnaire) between study groups.

Baseline M (SD)P Pre-T25 weeks M (SD)P 1 -PT6 months M (SD))P 2 -PT1 year M (SD)P 3 -PT
SF-36IGPGIGPGIGPGIGPG

PF49.43 (6.90)51.90 (9.92).19945.90 (5.87)50.53 (9.12).009*46.05 (4.61)49.05 (8.03).049*47.43 (5.32)50.68 (7.54).367
PR25.17 (6.88)25.86 (7.35).66122.10 (6.84)25.80 (6.98).019*23.85 (7.05)25.47 (7.09).06724.67 (7.24)26.01 (7.83).121
BP75.76 (7.20)78.43 (12.75).25773.12 (6.08)78.00 (13.07).036*74.25 (6.74)78.65 (13.22).05274.84 (7.04)77.39 (10.65).234
GH67.02 (4.25)68.28 (6.84).25864.40 (4.65)68.35 (6.39).048*66.02 (4.12)67.92 (6.69).08766.72 (5.21)67.63 (7.02).321
V60.05 (5.23)58.90 (6.27).37662.73 (5.27)59.48 (7.73).046*60.80 (5.11)58.72 (7.78).050*61.34 (4.96)59.01 (5.74).201
SF63.23 (7.12)63.93 (12.41).75858.75 (6.74)63.50 (11.57).028*59.85 (10.93)63.05 (11.87).07560.45 (8.67)64.45 (10.29).067
RE49.18 (7.65)46.35 (5.69).06545.60 (7.85)47.23 (5.66).29249.65 (6.52)46.40 (5.96).05348.33 (8.31)47.42 (7.29).135
MH76.65 (11.23)80.60 (9.66).09777.48 (8.73)81.15 (10.42).06974.15 (12.12)77.80 (7.84).07475.64 (9.86)79.45 (10.35).083

Values are presented as means and standard deviations (SD). IG, intervention group; PG, placebo group; Pre-T, pre-therapy; 1 PT, post-therapy after 25 weeks of treatment; 2 PT, post-therapy at 6 months after end of treatment; 3 PT, post-therapy at 1 year after end of treatment; PF, physical function; PR, physical role; BP, body pain; GH, general health; V, vitality; SF, social function; ER, emotional role; MH, mental health. *P = .05 (95% CI).